Synopsis: In this AI Leadership Insights video interview, Amanda Razani speaks with Thomas Swalla, CEO of Dotmatics, about how AI is being used to transform scientific research and drug discovery processes.
In this Leadership Insights interview, Amanda Razani speaks with Thomas Swalla, CEO of Dotmatics, about the transformative role of AI in scientific research and drug discovery. Swalla highlights the traditionally long and expensive process of bringing new drugs to market, noting how AI has the potential to drastically reduce both the time and cost involved. He explains that AI, particularly through language models and machine learning, can analyze complex data sets to identify patterns and targets that were previously difficult to detect, making drug discovery more efficient and effective.
Swalla also discusses the challenges of implementing AI, particularly the need for a robust data infrastructure. He emphasizes that AI is only as good as the data it processes, and that much of the current effort in the industry is focused on harmonizing and structuring siloed data to make it AI-ready. Despite these challenges, Swalla remains optimistic about the future, noting that AI is already being used successfully in various applications within life sciences and predicting significant breakthroughs in the near future. The interview concludes with Swalla’s belief that AI will revolutionize drug discovery.
